Celularity Statistics
Total Valuation
Celularity has a market cap or net worth of $69.92 million. The enterprise value is $113.83 million.
| Market Cap | 69.92M |
| Enterprise Value | 113.83M |
Important Dates
The next estimated earnings date is Monday, May 20, 2024, after market close.
| Earnings Date | May 20, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Celularity has 21.78 million shares outstanding. The number of shares has increased by 25.09% in one year.
| Shares Outstanding | 21.78M |
| Shares Change (YoY) | +25.09% |
| Shares Change (QoQ) | +6.66% |
| Owned by Insiders (%) | 50.95% |
| Owned by Institutions (%) | 14.66% |
| Float | 9.49M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.73 |
| Forward PS | n/a |
| PB Ratio | 2.31 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.70 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.20, with a Debt / Equity ratio of 2.02.
| Current Ratio | 0.20 |
| Quick Ratio | 0.25 |
| Debt / Equity | 2.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -76.12 |
Financial Efficiency
Return on equity (ROE) is -144.20% and return on invested capital (ROIC) is -378.09%.
| Return on Equity (ROE) | -144.20% |
| Return on Assets (ROA) | -62.20% |
| Return on Capital (ROIC) | -378.09% |
| Revenue Per Employee | $65,724 |
| Profits Per Employee | -$806,258 |
| Employee Count | 225 |
| Asset Turnover | 0.05 |
| Inventory Turnover | 0.63 |
Taxes
In the past 12 months, Celularity has paid $13,000 in taxes.
| Income Tax | 13,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -56.99% in the last 52 weeks. The beta is 0.30, so Celularity's price volatility has been lower than the market average.
| Beta (1Y) | 0.30 |
| 52-Week Price Change | -56.99% |
| 50-Day Moving Average | 4.75 |
| 200-Day Moving Average | 3.37 |
| Relative Strength Index (RSI) | 30.22 |
| Average Volume (30 Days) | 112,162 |
Short Selling Information
The latest short interest is 415,805, so 1.91% of the outstanding shares have been sold short.
| Short Interest | 415,805 |
| Short Previous Month | 388,267 |
| Short % of Shares Out | 1.91% |
| Short % of Float | 4.38% |
| Short Ratio (days to cover) | 3.44 |
Income Statement
In the last 12 months, Celularity had revenue of $14.79 million and -$181.41 million in losses. Loss per share was -$10.20.
| Revenue | 14.79M |
| Gross Profit | -3.70M |
| Operating Income | -345.29M |
| Pretax Income | -181.40M |
| Net Income | -181.41M |
| EBITDA | -169.66M |
| EBIT | -179.04M |
| Loss Per Share | -$10.20 |
Balance Sheet
The company has $17.17 million in cash and $61.08 million in debt, giving a net cash position of -$43.91 million or -$2.02 per share.
| Cash & Cash Equivalents | 17.17M |
| Total Debt | 61.08M |
| Net Cash | -43.91M |
| Net Cash Per Share | -$2.02 |
| Equity / Book Value | 30.25M |
| Book Value Per Share | 1.39 |
| Working Capital | -68.13M |
Cash Flow
In the last 12 months, operating cash flow was -$63.93 million and capital expenditures -$1.25 million, giving a free cash flow of -$65.18 million.
| Operating Cash Flow | -63.93M |
| Capital Expenditures | -1.25M |
| Free Cash Flow | -65.18M |
| FCF Per Share | -$3.46 |
Margins
Gross margin is -25.05%, with operating and profit margins of -2,334.95% and -1,226.72%.
| Gross Margin | -25.05% |
| Operating Margin | -2,334.95% |
| Pretax Margin | -1,226.64% |
| Profit Margin | -1,226.72% |
| EBITDA Margin | -1,147.25% |
| EBIT Margin | -1,210.73% |
| FCF Margin | -440.74% |
Dividends & Yields
Celularity does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -25.09% |
| Shareholder Yield | -25.09% |
| Earnings Yield | -259.44% |
| FCF Yield | -93.21% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on February 29, 2024. It was a reverse split with a ratio of 1:10.
| Last Split Date | Feb 29, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
Celularity has an Altman Z-Score of -11.44 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -11.44 |
| Piotroski F-Score | 3 |